Literature DB >> 34117891

What do surgeons need to know about the mesopancreas.

Eduardo de Souza M Fernandes1,2, Oliver Strobel3,4, Camila Girão1,2, Jose Maria A Moraes-Junior5,6, Orlando Jorge M Torres7,8.   

Abstract

BACKGROUND: Pancreatoduodenectomy is the only treatment with a promise of cure for patients with pancreatic head adenocarcinoma, and a negative resection margin is an important factor related to overall survival. Complete clearance of the medial margin with removal of the so-called mesopancreas may decrease the recurrence rate after pancreatic resection. Here, we present some important information about the mesopancreas, total mesopancreas excision, and technical aspects to achieve negative resection margins. The area named mesopancreas is defined as the tissue located between the head of the pancreas and the superior mesenteric vessels and the celiac axis and consists of the nerve plexus, lymphatic tissue, and connective tissue. The superior mesenteric and celiac arteries define the border of the mesopancreas. En bloc resection of anterior and posterior pancreatoduodenal nodes, hepatoduodenal nodes, along the superior mesenteric artery nodes, pyloric nodes, and nodes along the common hepatic artery is necessary.
CONCLUSIONS: Improved knowledge of the surgical anatomy of the region and technical refinements of excision of the mesopancreas along with standardized pathological examination are important to increase and to determine radical resection of pancreatic head cancer.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Mesopancreas; Negative margins; Pancreatic head plexus; Retroportal lamina; Survival; Total mesopancreas excision 

Mesh:

Year:  2021        PMID: 34117891     DOI: 10.1007/s00423-021-02211-y

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  45 in total

1.  Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail.

Authors:  T Hank; U Hinz; I Tarantino; J Kaiser; W Niesen; F Bergmann; T Hackert; M W Büchler; O Strobel
Journal:  Br J Surg       Date:  2018-05-08       Impact factor: 6.939

2.  Staging of pancreatic cancer based on the number of positive lymph nodes.

Authors:  I Tarantino; R Warschkow; T Hackert; B M Schmied; M W Büchler; O Strobel; A Ulrich
Journal:  Br J Surg       Date:  2017-02-14       Impact factor: 6.939

3.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Authors:  Thierry Conroy; Pascal Hammel; Mohamed Hebbar; Meher Ben Abdelghani; Alice C Wei; Jean-Luc Raoul; Laurence Choné; Eric Francois; Pascal Artru; James J Biagi; Thierry Lecomte; Eric Assenat; Roger Faroux; Marc Ychou; Julien Volet; Alain Sauvanet; Gilles Breysacher; Frédéric Di Fiore; Christine Cripps; Petr Kavan; Patrick Texereau; Karine Bouhier-Leporrier; Faiza Khemissa-Akouz; Jean-Louis Legoux; Béata Juzyna; Sophie Gourgou; Christopher J O'Callaghan; Claire Jouffroy-Zeller; Patrick Rat; David Malka; Florence Castan; Jean-Baptiste Bachet
Journal:  N Engl J Med       Date:  2018-12-20       Impact factor: 91.245

4.  Redefining the R1 resection in pancreatic cancer.

Authors:  C S Verbeke; D Leitch; K V Menon; M J McMahon; P J Guillou; A Anthoney
Journal:  Br J Surg       Date:  2006-10       Impact factor: 6.939

5.  Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.

Authors:  Eva Versteijne; Mustafa Suker; Karin Groothuis; Janine M Akkermans-Vogelaar; Marc G Besselink; Bert A Bonsing; Jeroen Buijsen; Olivier R Busch; Geert-Jan M Creemers; Ronald M van Dam; Ferry A L M Eskens; Sebastiaan Festen; Jan Willem B de Groot; Bas Groot Koerkamp; Ignace H de Hingh; Marjolein Y V Homs; Jeanin E van Hooft; Emile D Kerver; Saskia A C Luelmo; Karen J Neelis; Joost Nuyttens; Gabriel M R M Paardekooper; Gijs A Patijn; Maurice J C van der Sangen; Judith de Vos-Geelen; Johanna W Wilmink; Aeilko H Zwinderman; Cornelis J Punt; Casper H van Eijck; Geertjan van Tienhoven
Journal:  J Clin Oncol       Date:  2020-02-27       Impact factor: 44.544

6.  Recurrence patterns of pancreatic cancer after pancreatoduodenectomy: systematic review and a single-centre retrospective study.

Authors:  Marit Kalisvaart; Damian Broadhurst; Francesca Marcon; Rupaly Pande; Andrea Schlegel; Robert Sutcliffe; Ravi Marudanayagam; Darius Mirza; Nikolaos Chatzizacharias; Manuel Abradelo; Paolo Muiesan; John Isaac; Yuk T Ma; Christopher McConville; Keith Roberts
Journal:  HPB (Oxford)       Date:  2020-02-08       Impact factor: 3.647

7.  Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

Authors:  John P Neoptolemos; Daniel H Palmer; Paula Ghaneh; Eftychia E Psarelli; Juan W Valle; Christopher M Halloran; Olusola Faluyi; Derek A O'Reilly; David Cunningham; Jonathan Wadsley; Suzanne Darby; Tim Meyer; Roopinder Gillmore; Alan Anthoney; Pehr Lind; Bengt Glimelius; Stephen Falk; Jakob R Izbicki; Gary William Middleton; Sebastian Cummins; Paul J Ross; Harpreet Wasan; Alec McDonald; Tom Crosby; Yuk Ting Ma; Kinnari Patel; David Sherriff; Rubin Soomal; David Borg; Sharmila Sothi; Pascal Hammel; Thilo Hackert; Richard Jackson; Markus W Büchler
Journal:  Lancet       Date:  2017-01-25       Impact factor: 79.321

8.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.

Authors:  John P Neoptolemos; Deborah D Stocken; Helmut Friess; Claudio Bassi; Janet A Dunn; Helen Hickey; Hans Beger; Laureano Fernandez-Cruz; Christos Dervenis; François Lacaine; Massimo Falconi; Paolo Pederzoli; Akos Pap; David Spooner; David J Kerr; Markus W Büchler
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245

Review 9.  Optimizing the outcomes of pancreatic cancer surgery.

Authors:  Oliver Strobel; John Neoptolemos; Dirk Jäger; Markus W Büchler
Journal:  Nat Rev Clin Oncol       Date:  2019-01       Impact factor: 66.675

Review 10.  Local radicality and survival outcome of pancreatic cancer surgery.

Authors:  Willem Niesen; Thomas Hank; Markus Büchler; Oliver Strobel
Journal:  Ann Gastroenterol Surg       Date:  2019-07-01
View more
  2 in total

1.  ASO Author Reflections: The Importance of the Mesopancreas Excision During Pancreatoduodenectomies.

Authors:  Marcel Autran Machado; Fabio Makdissi
Journal:  Ann Surg Oncol       Date:  2021-08-04       Impact factor: 5.344

2.  COMBINED VENOUS AND ARTERIAL RECONSTRUCTION IN THE TRIANGLE AREA AFTER TOTAL PANCREATODUODENECTOMY.

Authors:  Eduardo de Souza Martins Fernandes; Jose Maria Assunção Moraes-Junior; Rodrigo Rodrigues Vasques; Marcos Belotto; Orlando Jorge Martins Torres
Journal:  Arq Bras Cir Dig       Date:  2022-06-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.